AC-262,536
AC-262536 is a drug developed by Acadia Pharmaceuticals which acts as a selective androgen receptor modulator (SARM). Chemically it possesses endo-exo isomerism, with the endo form being the active form. It acts as a partial agonist for the androgen receptor with a Ki of 5nM, and no significant affinity for any other receptors tested. In animal studies it produced a maximal effect of around 66% of the anabolic action of testosterone, but only around 27% of its potency as an androgen.[1]
 | |
| Identifiers | |
|---|---|
IUPAC name
| |
| CAS Number |
|
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C18H18N2O |
| Molar mass | 278.348 g/mol g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
References
- Piu, F; Gardell, LR; Son, T; Schlienger, N; Lund, BW; Schiffer, HH; Vanover, KE; Davis, RE; Olsson, R; Bradley, SR (2008). "Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator". The Journal of Steroid Biochemistry and Molecular Biology. 109 (1–2): 129–37. doi:10.1016/j.jsbmb.2007.11.001. PMID 18164613.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.